Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Nakajima TE, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W. Fujitani K, et al. Among authors: moriwaki t. Gastric Cancer. 2021 Mar;24(2):467-476. doi: 10.1007/s10120-020-01131-y. Epub 2020 Nov 2. Gastric Cancer. 2021. PMID: 33136231 Free PMC article. Clinical Trial.
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Matsubara J, et al. Among authors: moriwaki t. Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29. Br J Cancer. 2008. PMID: 18231104 Free PMC article.
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I. Moriwaki T, et al. Med Oncol. 2012 Dec;29(4):2842-8. doi: 10.1007/s12032-011-0151-2. Epub 2011 Dec 31. Med Oncol. 2012. PMID: 22209842
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Moriwaki T, Hirai S, Hironaka S, Amagai K, Soeda A, Sato M, Nihei T, Hirose M, Matsuda K, Ohkawara A, Yamaguchi T, Ozeki M, Mamiya T, Murashita T, Hyodo I. Moriwaki T, et al. Gastric Cancer. 2014 Apr;17(2):354-61. doi: 10.1007/s10120-013-0284-4. Epub 2013 Jul 13. Gastric Cancer. 2014. PMID: 23852397 Clinical Trial.
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Hironaka S, et al. Among authors: moriwaki t. J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4. J Clin Oncol. 2013. PMID: 24190112 Clinical Trial.
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group, Tokyo, Japan. Higuchi K, et al. Among authors: moriwaki t. Eur J Cancer. 2014 May;50(8):1437-45. doi: 10.1016/j.ejca.2014.01.020. Epub 2014 Feb 20. Eur J Cancer. 2014. PMID: 24560487 Clinical Trial.
Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study.
Moriwaki T, Kajiwara T, Matsumoto T, Suzuki H, Hiroshima Y, Matsuda K, Hirai S, Yamamoto Y, Yamada T, Sugaya A, Kobayashi M, Endo S, Ishige K, Nishina T, Hyodo I. Moriwaki T, et al. Dis Esophagus. 2014 Nov-Dec;27(8):737-43. doi: 10.1111/dote.12246. Epub 2014 Jun 11. Dis Esophagus. 2014. PMID: 24917486
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. Ichikawa W, et al. Among authors: moriwaki t. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880011 Free PMC article.
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T, Kato T, Yamazaki K, Yoshino T, Miyata Y, Esaki T, Moriwaki T, Boku N, Hyodo I. Nishina T, et al. Among authors: moriwaki t. Cancer Chemother Pharmacol. 2015 Sep;76(3):547-53. doi: 10.1007/s00280-015-2825-5. Epub 2015 Jul 22. Cancer Chemother Pharmacol. 2015. PMID: 26198316 Clinical Trial.
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, Tsuji A, Nakajima TE, Gotoh M, Machida N, Bando H, Esaki T, Emi Y, Sekikawa T, Matsumoto S, Takeuchi M, Boku N, Baba H, Hyodo I. Hironaka S, et al. Among authors: moriwaki t. Lancet Oncol. 2016 Jan;17(1):99-108. doi: 10.1016/S1470-2045(15)00410-6. Epub 2015 Nov 28. Lancet Oncol. 2016. PMID: 26640036 Clinical Trial.
303 results